- 不限
- 乙肝治愈转化医学研究 Translational study for functional cure of chronic HBV infection
- 肝癌及门脉高压治疗 Treatment of liver cancer and portal hypertension
- 肝衰竭、人工肝、重症感染 Liver failure, artificial liver, severe infection
- 肿瘤免疫治疗及转化研究 Tumor Immunotherapy and Translational Research
- 精准医学高峰论坛 Precision Medicine Summit Forum
- 国际消除病毒性肝炎论坛 International Forum on Elimination of Viral Hepatitis
- 新药研发热点 New drug research and development hotspots
- 中法肝病论坛：肝病无创诊断技术最新进展及应用 Sino-French Liver Diseases Forum：Advancement & Application of Non-invasive Diagnostic Technology
- 传染病国家级平台学科建设高峰论坛 National Platform for Discipline Construction of Infectious Diseases Summit Forum
- 介入专场 Intervention Session
- 医防融合：社区和MDT管理培训 Medical and prevention integration: community and MDT management training
- 不限
- 2021-12-10 [星期五]
- 2021-12-11 [星期六]
- 2021-12-12 [星期日]
- 不限
- 主会场（大沙龙厅） The Main Venue（Dashalong Hall）
- 大沙龙厅1 Dashalong Hall 1
- 大沙龙厅2 Dashalong Hall 2
- 大沙龙厅3 Dashalong Hall 3
2021-12-11 星期六
大沙龙厅3 Dashalong Hall 3
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:45 |
DILI研究进展和诊疗中应注意的问题 |
陈成伟 | 中国人民解放军海军第九〇五医院 |
|
Research progress of DILI and issues needing attention in diagnosis and treatment |
Chengwei Chen | 905 Hospital of PLA Navy | |
| 13:45-14:00 |
乙肝新药研发的热点问题 |
牛俊奇 | 吉林大学第一医院 |
|
Hot issues in research and development of new hepatitis B drugs |
Junqi NIU | The first hospital of Jilin University | |
| 14:00-14:15 |
乙肝受体相关抗体药物 |
李文辉 | 北京生命科学研究所 |
|
Hepatitis B Receptor Related Antibody Drugs |
Wenhui LI | National Institute of Biological Sciences, Beijing | |
| 14:15-14:30 |
乙肝RNA药物研发思考 |
吴旻 | 安力高医药（上海）有限公司 |
|
Thoughts on development of hepatitis B RNA drugs |
Min Wu | Aligos Therapeutics | |
| 14:30-14:45 |
乙肝新药联合治疗的设计和策略 |
贾继东 | 首都医科大学附属北京友谊医院 |
|
Design and strategy of new hepatitis B drug combination therapy |
Jidong Jia | Beijing Friendship Hospital Capital Medical University | |
| 14:45-15:00 |
乙肝标志物在新药研发的价值 |
鲁凤民 | 北京大学基础医学院 |
|
Value of hepatitis B markers in the development of new drugs |
Fengmin LU | School of basic medicine Peking University | |
| 15:00-15:15 |
靶向细胞凋亡通路新药转化研究与开发 |
YANG DAJUN | 亚盛医药 |
| Dajun Yang |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:30-15:45 |
NASH中国和国外临床研究 |
魏来 | 清华大学附属北京清华长庚医院 |
|
NASH clinical research in China and abroad |
Lai WEI | Beijing Tsinghua Changgung Hospital | |
| 15:45-16:00 |
门脉高压新药研发挑战和机遇 |
王建华 | 广州力鑫生物科技有限公司 |
|
The research and development of new drugs for portal hypertension：Challenge and opportunities |
Jianhua Wang | Guangzhou Lixin Pharmaceutical Biotechnology | |
| 16:00-16:15 |
肝纤维化的定量诊断 |
汪艳 | 南方医科大学 |
|
Quantitative diagnosis of liver fibrosis |
Yan Wang | Southern Medical University | |
| 16:15-16:30 |
cccDNA代谢池和新药研发 |
孙剑 | 南方医科大学南方医院 |
|
cccDNA metabolic pool and new drug development |
Jian SUN | Nanfang Hospital, Southern Medical University | |
| 16:30-16:45 |
放射性粒子增敏剂的研制 |
张福君 | 中山大学肿瘤防治中心 |
|
Development of radioactive particle sensitizer |
Fujun Zhang | Tumor Radioactive Particle Innovation Center | |
| 16:45-17:00 |
聚焦乙肝功能性治愈：新靶点新策略 |
黄琦 | 华辉安健（北京）生物科技有限公司 |
|
Focus on the functional cure of hepatitis B: new targets and new strategies |
Qi Huang | Huahui Anjian (Beijing) Biotechnology | |
| 17:00-17:15 |
肝脏疾病中的AI数字病理学——提高对病理生物学和治疗应答的认识 |
Nikolai Naoumov | London, UK |
|
AI digital pathology in liver diseases – improved understanding of pathobiology and treatment response |
Nikolai Naoumov | London, UK | |
| 17:15-17:30 |
肝脏疾病中的ALBI评分 |
Philip Johnson | 利物浦大学 |
|
ALBI score in liver disease |
Philip Johnson | University of Liverpool | |
| 17:30-17:45 |
IAP抑制剂清除HBV感染的临床前研究 |
张小勇 | 南方医科大学南方医院 |
|
Preclinical study of IAP inhibitor to clear HBV infection |
Xiaoyong Zhang | Nanfang Hospital, Southern Medical University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 17:45-18:05 |
专题研讨会：恒沐-最新原研二代替诺福韦48周疗效及安全性 |
牛俊奇 | 吉林大学第一医院 |
|
Symposium: Hengmu- the efficacy and safety of the latest TAF in 48 weeks |
Junqi NIU | The first hospital of Jilin University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 18:05-18:25 |
专题研讨会：关注慢乙肝合并血脂异常患者的安全用药 |
杨晴 | 珠海市人民医院 |
|
Symposium: Focus on safe medication of patients with chronic hepatitis B and dyslipidemia |
Qing Yang | Zhuhai People's Hospital |
美迪康会务通